TMCnet
Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy
Tenaya is currently implementing amendments to the study protocol in collaboration with MyPEAK-1 clinical sites after which the company plans to resume dosing. The protocol changes standardize ...
Morningstar
First Clinical Investigation of a Gene Therapy (YAP101) to Induce Cardiac Regeneration to Treat Heart Failure Passes Initial Safety Hurdle
Medley Therapeutics (formerly YAP Therapeutics) has dosed the first cohort (n=3) with YAP101 in the Phase 1 SALVADOR-HF trial at The Texas Heart Institute at Baylor College of Medicine in the Baylor ...
FierceBiotech
ASGCT: Analysts see Rocket gene therapy setting 'a new bar' for efficacy in heart condition
Rocket Pharmaceuticals has shared early data from three patients that tie its gene therapy for an inherited heart disease to a well-tolerated safety profile, which has been heralded by analysts as ...
Morningstar
AskBio Presents Complete Results of Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure at European Society of Cardiology Heart Failure Meeting
First-in-human trial of AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York Heart Association (NYHA) Class III heart failure Trial enrolled 11 participants in ...
Business Insider
Medera Announces First Patient Dosed in Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial Evaluating SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction
BOSTON, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, ...
GEN
Gene Therapy Companies Set Sights on Cardiovascular Disease
Gene therapy achieved its first major breakthroughs in the early 1990s with the treatment of a rare disease called severe combined immunodeficiency. However, the field was dealt a serious setback in ...